Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer
Objectives: Inhibition of the PI3K/mTOR pathway suppresses breast cancer (BC) growth, enhances anti-tumor immune responses, and works synergistically with immune checkpoint inhibitors (ICI). The objective here was to identify a subclass of PI3K inhibitors that, when combined with paclitaxel, is effe...
Main Authors: | Chi Yan, Jinming Yang, Nabil Saleh, Sheau-Chiann Chen, Gregory D. Ayers, Vandana G. Abramson, Ingrid A. Mayer, Ann Richmond |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-05-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/10/5207 |
Similar Items
-
PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
by: Kunrui Zhu, et al.
Published: (2022-08-01) -
Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer
by: Huayi Li, et al.
Published: (2021-07-01) -
Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges
by: Krisida Cerma, et al.
Published: (2023-01-01) -
Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer
by: Mirjana Prvanović, et al.
Published: (2021-11-01) -
PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities
by: Wojciech Wiese, et al.
Published: (2023-11-01)